aTyr Pharma Inc.
3545 John Hopkins Road, Suite 250
San Diego
California
92121
United States
227 articles with aTyr Pharma Inc.
-
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference
1/31/2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data on the mechanism of action (MOA) and exposure-efficacy analysis for its lead therapeutic candidate, efzofitimod, in an oral symposia presentation and poster session, respectively, at the American Thoracic Society (ATS) 2023 International Conference.
-
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
1/19/2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Patent Office (EPO) has provided a Notice of Allowance for a patent covering methods for the use of histidyl-tRNA synthetase (HARS) Fc fusion proteins for reducing inflammation or fibrosis in the lung.
-
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of SarcoidosisGlobal pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe
1/18/2023
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
-
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
12/15/2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced new findings from its tRNA synthetase platform.
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 18, 2022
11/18/2022
aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 13,200 shares of its common stock, each with an exercise price of $2.38 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on November 16, 2022, the effective date of the grants.
-
aTyr Pharma to Present at Upcoming Investor Conferences
11/10/2022
aTyr Pharma, Inc. today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences scheduled to take place in November and December 2022.
-
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
11/10/2022
aTyr Pharma, Inc. announced third quarter 2022 results and provided a corporate update.
-
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
11/9/2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication in the journal CHEST of positive results from a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease.
-
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
11/3/2022
aTyr Pharma, Inc. announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022.
-
aTyr Pharma to Present at the Jefferies 2022 London Healthcare Conference
10/25/2022
aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the Jefferies London Healthcare Conference, which is scheduled to take place November 15 – 17, 2022, in London, U.K.
-
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
10/11/2022
aTyr Pharma, Inc. today announced that it has entered into a research collaboration with Dualsystems Biotech AG, a company specializing in custom proteomics, aimed at accelerating drug discovery and generating new therapeutics based on aTyr’s extensive intellectual property.
-
aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
10/4/2022
aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview as part of the RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium, which is scheduled to take place virtually on Friday, October 7, 2022.
-
aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies
9/29/2022
aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced that the U.S. Patent and Trademark Office has provided a Notice of Allowance for a patent covering methods for the use of anti-neuropilin-2 antibodies.
-
aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
9/27/2022
aTyr Pharma, Inc. today announced that it has dosed the first patient in the global pivotal EFZO-FIT™ study.
-
The FDA has a broad range of activities in the drug and medical device space. Here’s a look at the agency’s work this week.
-
aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
9/13/2022
Second Fast Track designation for efzofitimod clinical program.
-
aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
9/6/2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference.
-
aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022
9/1/2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday, September 5, 2022, from 8:30AM – 9:30AM CEST at the European Respiratory Society (ERS) International Congress 2022 in Barcelona, Spain.
-
aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update
8/15/2022
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2022 results and provided a corporate update.
-
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 12, 2022
8/12/2022
aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 20,600 shares of its common stock, each with an exercise price of $3.70 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on August 8, 2022, the effective date of the grants.